COMMUNIQUÉS West-GlobeNewswire
-
Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics
11/11/2024 - 22:05 -
Sienna Senior Living Inc. Reports Strong Third Quarter 2024 Financial Results and Continues on its Growth Path
11/11/2024 - 22:15 -
Precision Optics Corporation Schedules First Quarter of Fiscal Year 2025 Conference Call for November 14, 2024
11/11/2024 - 22:15 -
DBV Technologies annonce son intention de modifier le ratio d'ADS
11/11/2024 - 22:30 -
DBV Technologies Announces Plan to Implement ADS Ratio Change
11/11/2024 - 22:30 -
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib)
11/11/2024 - 22:35 -
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
11/11/2024 - 22:36 -
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
09/11/2024 - 23:30 -
KFSHRC’s New US Patent Opens New Frontiers for Breast Cancer Treatment
10/11/2024 - 13:26 -
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA⁽¹⁾ and Revises Upwards 2024 Financial Guidance Ranges
10/11/2024 - 22:15 -
Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME
08/11/2024 - 23:00 -
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/11/2024 - 23:30 -
Revolutionizing Prescription Management: Ironsail Pharma Launches Advanced Pharmacy Network Technology
08/11/2024 - 23:40 -
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
09/11/2024 - 16:30 -
Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)
09/11/2024 - 19:00 -
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
09/11/2024 - 19:30 -
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
09/11/2024 - 19:40 -
Humacyte Third Quarter 2024 Financial Results and Business Update
08/11/2024 - 14:00 -
Spectral Medical Announces Third Quarter Results and Provides Corporate Update
08/11/2024 - 14:00
Pages